Last reviewed · How we verify
SP-104
At a glance
| Generic name | SP-104 |
|---|---|
| Sponsor | Scilex Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) (PHASE1)
- Effects of Dronabinol in Opioid Maintained Patients (EARLY_PHASE1)
- Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment (PHASE2)
- Dronabinol as an Adjunct for Reducing Pain (PHASE2)
- Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital (PHASE2)
- Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP-104 CI brief — competitive landscape report
- SP-104 updates RSS · CI watch RSS
- Scilex Pharmaceuticals, Inc. portfolio CI